Related Experiment Video
Updated: Jun 27, 2026
07:01
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
Published on: March 1, 2020
[Serum galectin-9 in cervical cancer]
Mei-yan Liang1, Yan-ming Lu, Yao Zhang
1Department of Gynecology and Obstetrics, Shengjing Hospital, China Medical University, Shenyang 110004, China.
Zhonghua Yi Xue Za Zhi
|December 17, 2008
Summary
Serum Galectin-9 (Gal-9) levels are elevated in cervical cancer patients, correlating with disease progression and potentially originating from tumor tissue. Further research is warranted to understand its role.
Area of Science:
- Oncology
- Biochemistry
- Immunology
Context:
- Cervical cancer is a significant global health concern.
- Biomarkers are crucial for early detection and monitoring of cancer.
- Galectin-9 (Gal-9) is a protein with potential roles in immune regulation and cancer.
Purpose:
- To investigate the serum expression levels of Galectin-9 (Gal-9) in patients with cervical cancer.
- To analyze the clinical significance of Gal-9 in cervical cancer.
- To explore the relationship between Gal-9, vascular endothelial growth factor (VEGF), and C-reactive protein (CRP) in cervical cancer.
Summary:
- Serum Gal-9 concentrations were significantly higher in cervical cancer patients (27.15 ng/L) compared to those with cervical intraepithelial neoplasia (CIN) (21.20 ng/L) and normal controls (17.43 ng/L).
- Gal-9 levels showed a significant correlation with serum VEGF and CRP in the cervical cancer group.
- Immunohistochemical analysis suggested that cervical cancer tissue may contribute to serum Gal-9 levels.
Impact:
- Galectin-9 may serve as a potential biomarker for cervical cancer detection and progression.
- Understanding Gal-9's role could lead to novel therapeutic strategies for cervical cancer.
- This study highlights the need for further investigation into Gal-9's function in cervical carcinogenesis.
